GIP Antikörper (AA 52-93)

Produktnummer ABIN4886602

Dieses Kaninchen Polyklonal-Antikörper erkennt spezifisch GIP in WB und IHC. Er zeigt eine Reaktivität gegenüber Human und Ratte.

Kurzübersicht für GIP Antikörper (AA 52-93) (ABIN4886602)

Target: GIP (Gastric Inhibitory Polypeptide (GIP))

Reaktivität: Human, Ratte

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Dieser GIP Antikörper ist unkonjugiert

Applikation: Western Blotting (WB), Immunohistochemistry (IHC)

Produktdetails anti-GIP Antikörper

Bindungsspezifität: AA 52-93

Verwendungszweck: Anti-GIP Antibody Picoband®

Kreuzreaktivität (Details): No cross-reactivity with other proteins

Produktmerkmale: Anti-GIP Antibody Picoband® (ABIN4886602). Tested in IHC, WB applications. This antibody reacts with Human, Rat. The brand Picoband indicates this is a premium antibody that guarantees superior quality, high affinity, and strong signals with minimal background in Western blot applications. Only our best-performing antibodies are designated as Picoband, ensuring unmatched performance.

Aufreinigung: Immunogen affinity purified.

Immunogen: E. coli-derived human GIP recombinant protein (Position: Y52-Q93). Human GIP shares 92.9% and 95.2% amino acid (aa) sequence identity with mouse and rat GIP, respectively.

Isotyp: IgG

Anwendungsinformationen

Applikationshinweise: Western blot, 0.1-0.5 μg/mL, Human
Immunohistochemistry (Paraffin-embedded Section), 2-5 μg/mL, Human, Rat
1. Gaudin-Audrain C, Irwin N, Mansur S, Flatt PR, Thorens B, Baslé M, Chappard D, Mabilleau G (Mar 2013). "Glucose-dependent insulinotropic polypeptide receptor deficiency leads to modifications of trabecular bone volume and quality in mice". Bone 53 (1): 221-30. 2. Mieczkowska A, Irwin N, Flatt PR, Chappard D, Mabilleau G (Oct 2013). "Glucose-dependent insulinotropic polypeptide (GIP) receptor deletion leads to reduced bone strength and quality".Bone 56 (2): 337-42.

Kommentare:

Antibody can be supported by chemiluminescence kit ABIN921124 in WB, supported by ABIN921231 in IHC(P).

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Lyophilized

Rekonstitution: Add 0.2 mL of distilled water will yield a concentration of 500 μg/mL.

Konzentration: 500 μg/mL

Buffer: Each vial contains 4 mg Trehalose, 0.9 mg NaCl, 0.2 mg Na2HPO4, 0.01 mg Sodium azide.

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Handhabung: Avoid repeated freezing and thawing.

Lagerung: 4 °C,-20 °C

Informationen zur Lagerung: Store at -20°C for one year from date of receipt. After reconstitution, at 4°C for one month.
It can also be aliquotted and stored frozen at -20°C for six months. Avoid repeated freeze-thaw cycles.

Details zu GIP

Target: GIP (Gastric Inhibitory Polypeptide (GIP))

Andere Bezeichnung: GIP

Hintergrund:

Synonyms: Gastric inhibitory polypeptide,GIP,Glucose-dependent insulinotropic polypeptide,Incretin hormone,GIP,

Tissue Specificity: Predominantly expressed in kidney and brain. Detected at much lower levels in heart and skeletal muscle. .

Background: Gastric inhibitory polypeptide (GIP), also known as the glucose-dependent insulinotropic peptide, is an inhibiting hormone of the secretin family of hormones. GIP is thought to have significant effects on fatty acid metabolism through stimulation of lipoprotein lipase activity in adipocytes. Additionally, GIP release has been demonstrated in the ruminant animal and may play a role in nutrient partitioning in milk production (lipid metabolism). Recently, GIP appeared as a major player in bone remodelling. It was evidenced that genetic ablation of the GIP receptor in mice resulted in profound alterations of bone microarchitecture through modification of the adipokine network. Furthermore, the deficiency in GIP receptors has also been associated in mice with a dramatic decrease in bone quality and a subsequent increase in fracture risk.

Molekulargewicht: 17 kDa

Gen-ID: 2695

UniProt: P09681

Pathways: Positive Regulation of Peptide Hormone Secretion, Peptide Hormone Metabolism, Hormone Activity, Regulation of Lipid Metabolism by PPARalpha, Lipid Metabolism